Showing 1 - 10 of 44
Eptifibatide (Integrilin(R)) is a selective inhibitor of platelet glycoprotein IIb/IIIa receptors used as adjunctive therapy for patients undergoing percutaneous coronary intervention (PCI) and for patients with acute coronary syndromes (ACS), particularly those requiring PCI. Most economic...
Persistent link: https://www.econbiz.de/10005243019
Piperacillin/tazobactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity against most Gram-positive and Gram-negative aerobic bacteria and anaerobic bacteria. Piperacillin/tazobactam is effective and well-tolerated in patients with lower...
Persistent link: https://www.econbiz.de/10005243191
Memantine (Ebixa(R), Namenda(TM), Axura(R)) is an uncompetitive NMDA receptor antagonist used in the management of patients with moderate-to-severe Alzheimer's disease. It is currently the only drug approved for use in these more advanced stages of the disease. Significant reductions in...
Persistent link: https://www.econbiz.de/10005243220
This article briefly summarizes the burden of bipolar disorder and the clinical profile of quetiapine (Seroquel) in the management of bipolar disorder, followed by a detailed review of pharmacoeconomic analyses. Quetiapine is an atypical antipsychotic that is available in numerous countries as...
Persistent link: https://www.econbiz.de/10010551728
The most common cause of severe diarrhoea in infants and young children is rotavirus gastroenteritis (RVGE), which is associated with significant morbidity, healthcare resource use and direct and indirect costs in industrialized nations. The monovalent rotavirus vaccine RIX4414 (Rotarix™) is...
Persistent link: https://www.econbiz.de/10010614301
This article provides an overview of the clinical profile of rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis (RVGE) in developing countries, followed by a comprehensive review of pharmacoeconomic analyses with the vaccine in low- and middle-income countries....
Persistent link: https://www.econbiz.de/10010614303
This article provides an overview of the clinical profile of the calcimimetic agent cinacalcet (Mimpara, Sensipar) in the treatment of patients with secondary hyperparathyroidism (SHPT) undergoing dialysis for end-stage renal disease (ESRD), followed by a comprehensive review of pharmacoeconomic...
Persistent link: https://www.econbiz.de/10010614385
Piperacillin/tazobactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity against most Gram-positive and Gram-negative aerobic bacteria and anaerobic bacteria. Piperacillin/tazobactam is effective and well tolerated in patients with lower...
Persistent link: https://www.econbiz.de/10005448843
The addition of candesartan cilexetil (Atacand(R), Amias(R), Blopress(R), Kenzen(R), Ratacand(R)) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany, and the UK, according to a detailed economic analysis...
Persistent link: https://www.econbiz.de/10005448860
A number of first-line chemotherapy options for patients with advanced non-small cell lung cancer (NSCLC) are advocated in treatment guidelines and/or by various clinical investigators. Platinum-based chemotherapy has clearly demonstrated efficacy in patients with advanced NSCLC and is generally...
Persistent link: https://www.econbiz.de/10005448865